Correlation analysis of the combined detection of serum CEA, CA72-4, CA19-9 and PGI and postoperative recurrence of gastric cancer
Serum CEA, CA72-4, CA19-9 and PGI in postoperative recurrence of gastric cancer
Abstract
[Objective]: To determine if serum CEA, CA72-4, CA19-9, and PGI in gastric cancer patients following radical gastrectomy are associated with postoperative recurrence.
[Methods]: The gastric cancer group consisted of 102 patients who were admitted to our hospital between January 2022 and June 2024 and had undergone radical gastrectomy (RG); the control group consisted of 34 healthy volunteers who were examined during the same time period. Based on whether there was a recurrence following the procedure, patients with gastric cancer were split into two groups: 87 patients who did not experience a recurrence and 15 patients who did. The control group's serum levels of CEA, CA72-4, CA19-9, and PGI were assessed during physical examination, the day before surgery for gastric cancer patients, and at follow-up (or recurrence) one year later.
[Result] In the gastric cancer group, serum levels of PGI were lower than in the control group, whereas CEA, CA72-4, and CA19-9 were greater (all P<0.05). The recurrence rate (15/102 patients) was 14.71%. Poor differentiation degree, decreased PGI, and TNM stage III disease were all independent risk variables for recurrence following RG, according to univariate and multivariate logistic regression analyses (P<0.05). The sensitivity of the serum CEA level was 85.74%, and the specificity was 56.83%. The sensitivity of the serum CA72-4 concentration was 39.46%, and the specificity was 95.13%. Sensitivity of CA19-9 concentration was 58.91%, and the specificity was 78.11%. The AUC of the combined prediction of postoperative recurrence in patients with RG according to CEA, CA72-4, CA19-9 and PGI was greater than that of the individual predictions.
[Conclusion]: Patients with RG who had elevated CEA, CA72-4, and CA19-9, decreased PGI, TNM stage III, and little differentiation are at independent risk for postoperative recurrence.
References
2.Shang X, Zhao Y, Xu T, Ma Q, Su Z. Differential value of PGI, PGII and G-17 in chronic atrophic gastritis and early gastric cancer. Minerva Pediatr (Torino). 2023 Oct;75(5):753-755.
3.Deng D, Zhang Y, Zhang R, Yi J, Dong J, Sha L, Yan M. Circulating Proteins and Metabolite Biomarkers in Gastric Cancer: A Systematic Review and Meta-analysis. Arch Med Res. 2023 Feb;54(2):124-134.
4.Dondov G, Lonjid T, Badamjav T, Banzragch U, Tumurbat N, Amarbayasgalan D, Batbaatar B, Tuvdenjamts B, Davaa B, Batsaikhan B. Determining Gastric Cancer-Related Risk Factors in Mongolian Population Using ABC(D) Method: A Matched Case‒Control Study. Asian Pac J Cancer Prev. 2022 Mar 1;23(3):807-813.
5.Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, Pu J, Lv J. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023 Apr 28;29(16):2452-2468. Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024 Jul;10(7):627-642.
6.Christodoulidis G, Koumarelas KE, Kouliou MN. Revolutionizing gastric cancer treatment: The potential of immunotherapy. World J Gastroenterol. 2024 Jan 28;30(4):286-289.
7.Mamun TI, Younus S, Rahman MH. Gastric cancer-Epidemiology, modifiable and nonmodifiable risk factors, challenges and opportunities: An updated review. Cancer Treat Res Commun. 2024;41:100845.
8.Kono K, Nakajima S, Mimura K. Biomarker-oriented chemo-immunotherapy for advanced gastric cancer. Int J Clin Oncol. 2024 Jul;29(7):865-872.
9.Chen Y, Tang Z, Tang Z, Fu L, Liang G, Zhang Y, Tao C, Wang B. Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis. Int J Biol Macromol. 2025 Jan;287:138645.
10.Zhao N, Wang W, Jiang H, Qiao Z, Sun S, Wei Y, Xie X, Li H, Bi X, Yang Z. Natural Products and Gastric Cancer: Cellular Mechanisms and Effects to Change Cancer Progression. Anticancer Agents Med Chem. 2023;23(13):1506-1518.
11.Jiang X, Zhu Z, Ding L, Du W, Pei D. ALKBH4 impedes 5-FU Sensitivity through suppressing GSDME induced pyroptosis in gastric cancer. Cell Death Dis. 2024 Jun 20;15(6):435.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852.
13.Li P, Zhang H, Chen T, Zhou Y, Yang J, Zhou J. Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer. Matrix Biol. 2024 Sep;132:59-71.
14.Yang YN, Wang LS, Dang YQ, Ji G. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors. World J Gastroenterol. 2024 Aug 28;30(32):3726-3729.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248.
16.Mullen JT. Top Gastric Cancer Articles from 2022 and 2023 to Inform Your Cancer Practice. Ann Surg Oncol. 2024 Jun;31(6):3978-3983.
17.Deng J, Zhang W, Xu M, Zhou J. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. Abdom Radiol (NY). 2023 Dec;48(12):3661-3676.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861.
19.Pannu AK, Jhuria L, Bhalla A, Sharma N. PGI score: prospective validation and correlation with SOFA, SAPS-II, and APACHE-II scores for predicting outcomes in acute aluminum phosphide poisoning. Toxicol Res (Camb). 2022 Apr 1;11(2):361-366.
20.Shang X, Zhao Y, Xu T, Ma Q, Su Z. Differential value of PGI, PGII and G-17 in chronic atrophic gastritis and early gastric cancer. Minerva Pediatr (Torino). 2023 Oct;75(5):753-755.
21.Ritota M, Contò M, Failla S, Beni C, Macchioni A, Valentini M. PGI Chianina meat traceability by means of multivariate HRMAS-NMR data analysis. Anal Methods. 2025 Jan 2;17(2):291-299.
22.Ruggiero L, Amalfitano C, Agostini S, Adamo P. Strontium isotopic signature of the PGI lemons Limone Costa d'Amalfi and Limone di Sorrento, and of the orchard soils from Sorrento peninsula. Food Chem. 2024 Nov 30;459:139967.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603.
24.ElMehy AE, Sharif AF, Sobeeh FG. Prognostic value of PGI score compared to poison severity score (PSS) and simplified acute physiology score (SAPS) II as predictors of mortality and other adverse outcomes in acute poisoning with aluminum phosphide. Toxicol Rep. 2024 Aug 26;13:101718.
25.Ożga K, Stepuch P, Maciejewski R, Sadok I. Promising Gastric Cancer Biomarkers-Focus on Tryptophan Metabolism via the Kynurenine Pathway. Int J Mol Sci. 2025 Apr 14;26(8):3706.
26.Marano L, Carbone L, Poto GE, Restaino V, Piccioni SA, Verre L, Roviello F, Marrelli D. Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. Curr Oncol. 2023 Jan 8;30(1):875-896.
27.Liu Y, Shi Y, Han R, Liu C, Qin X, Li P, Gu R. Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer. Front Immunol. 2023 Apr 18;14:1139589.
Copyright (c) 2025 Bing Han, Yuli Yan, Yanyan Zhong, Xiaoou Li, Yong Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.